文献速递腹部介入US

在两个欧洲中心接受高强度聚焦超声(HIFU)治疗的胰腺癌患者生活质量改善情况

Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers.
PubMed 文献 · Eur Radiol · 2021-01-23

这项前瞻性两中心研究纳入80例晚期胰腺癌患者(德国50例、保加利亚30例),采用EORTC QLQ-C30问卷和NRS评估HIFU前后生活质量与疼痛。结果显示HIFU后3个月和6个月整体健康显著改善,6个月时躯体、情绪、社会功能及疼痛、疲乏、食欲丧失均改善,NRS显示各时间点疼痛均获有效缓解,且效果与肿瘤分期、转移状态及治疗国家无关。

要点

  • HIFU治疗后3个月和6个月整体健康较基线显著改善(p=0.02)。
  • HIFU后6个月躯体、情绪、社会功能及疼痛、疲乏、食欲丧失均显著改善。
  • NRS评估显示HIFU后各时间点疼痛均获有效且强烈的缓解(p<0.001)。

核心结论

  • HIFU是晚期胰腺癌的有效治疗选择,可提高整体健康并减轻躯体不适,且副作用发生率低,效果不依赖操作者。
  • 作者认为HIFU是除全身姑息化疗或最佳支持治疗外值得采用的附加治疗。

研究设计与样本

  • 前瞻性两中心研究,纳入80例晚期胰腺癌患者,德国50例、保加利亚30例,均接受HIFU治疗。
  • 采用EORTC QLQ-C30问卷在基线及HIFU后1、3、6个月评估生活质量和症状,并用数值评定量表(NRS)评估疼痛强度。

诊断标准与关键数值

  • 采用EORTC QLQ-C30问卷评估生活质量,NRS评估疼痛强度。
  • 与基线相比,HIFU后3个月和6个月整体健康显著改善(p=0.02)。
  • HIFU后6个月躯体功能(p=0.02)、情绪功能(p=0.01)、社会功能(p=0.01)显著改善。
  • HIFU后6个月疼痛(p=0.04)、疲乏(3个月p=0.03,6个月p=0.01)、食欲丧失(p=0.01)显著改善。
  • NRS评估显示HIFU后各时间点疼痛均获有效且强烈的缓解(p<0.001)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Pancreatic cancer patients often have a high symptom burden, significantly impairing patients' quality of life (QOL). Nevertheless, there are hardly any reports on the impact of high-intensity focused ultrasound (HIFU) on the QOL of treated patients. For the first time, this study evaluated the effect of HIFU on QOL and compared these results in two European centers.

METHODS: Eighty patients with advanced pancreatic cancer underwent HIFU (50 in Germany, 30 in Bulgaria). Clinical assessment included evaluation of QOL and symptoms using the EORTC QLQ-C30 questionnaire at baseline and 1, 3, and 6 months after HIFU. Pain intensity was additionally evaluated with the numerical rating score (NRS).

RESULTS: Compared to baseline, global health significantly improved 3 and 6 months after HIFU treatment (p = 0.02). Functional subscales including physical, emotional, and social functioning were considerably improved at 6 months (p = 0.02, p = 0.01, and p = 0.01, respectively) as were leading symptom pain (p = 0.04 at 6 months), fatigue (p = 0.03 at 3 and p = 0.01 at 6 months), and appetite loss (p = 0.01 at 6 months). Moreover, pain intensity measured by NRS revealed effective and strong pain relief at all time points (p < 0.001). Reported effects were independent of tumor stage, metastatic status, and country of treatment.

CONCLUSIONS: This study showed that HIFU represents an effective treatment option of advanced pancreatic cancer improving QOL by increasing global health and mitigation of physical complaints with a low rate of side effects, independent of the examiner. Therefore, HIFU is a worthwhile additional treatment besides systemic palliative chemotherapy or best supportive care in management of this aggressive disease.

KEY POINTS: • In a prospective two-center study, it was shown that HIFU represents an effective treatment option of advanced pancreatic cancer improving QOL. • HIFU in pancreatic cancer patients is associated with a low rate of side effects, independent of the performer. • HIFU is a worthwhile additional treatment besides systemic palliative chemotherapy or best supportive care in management of this aggressive disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Marinova M, Feradova H, Gonzalez-Carmona MA, et al. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers. Eur Radiol. 2021. PMID: 33486605. doi:10.1007/s00330-020-07682-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。